PURPOSE: To evaluate, in breast cancer patients treated by neoadjuvant chemotherapy, the predictive value of reduction in FDG uptake with regard to complete pathological response (pCR). METHODS: Forty-seven women with non-metastatic, non-inflammatory, large or locally advanced breast cancer were included. Tumour uptake of FDG was evaluated before and after the first course of neoadjuvant chemotherapy. Four indices were used: maximal and average SUV without or with correction by body surface area and glycaemia (SUV(max), SUV(avg), SUV(max-BSA-G) and SUV(avg-BSA-G), respectively). The predictive value of reduction in FDG uptake with respect to pCR was studied by logistic regression analysis. Relationships between baseline [(18)F]FDG uptake and prognostic parameters were assessed. RESULTS: The relative decrease in FDG uptake (DeltaSUV) after the first course of neoadjuvant chemotherapy was significantly greater in the pCR group than in the non-pCR group (p < 0.000066). The four FDG uptake indices were all strongly correlated with each other. A decrease in SUV(max-BSA-G) of 85.4% +/- 21.9% was found in pCR patients, versus 22.6% +/- 36.6% in non-pCR patients. DeltaSUV(max-BSA-G) <-60% predicted the pCR with an accuracy of 87% and DeltaSUVs were found to be only factors predictive of the pCR at multivariate analysis. An elevated baseline SUV was associated with high mitotic activity (p < 0.0016), tumour grading (p < 0.004), high nuclear pleomorphism score (p < 0.03) and negative hormonal receptor status (p < 0.005). CONCLUSION: In breast cancer patients, after only one course of neoadjuvant chemotherapy the reduction in FDG uptake is an early and powerful predictor of pCR.
PURPOSE: To evaluate, in breast cancerpatients treated by neoadjuvant chemotherapy, the predictive value of reduction in FDG uptake with regard to complete pathological response (pCR). METHODS: Forty-seven women with non-metastatic, non-inflammatory, large or locally advanced breast cancer were included. Tumour uptake of FDG was evaluated before and after the first course of neoadjuvant chemotherapy. Four indices were used: maximal and average SUV without or with correction by body surface area and glycaemia (SUV(max), SUV(avg), SUV(max-BSA-G) and SUV(avg-BSA-G), respectively). The predictive value of reduction in FDG uptake with respect to pCR was studied by logistic regression analysis. Relationships between baseline [(18)F]FDG uptake and prognostic parameters were assessed. RESULTS: The relative decrease in FDG uptake (DeltaSUV) after the first course of neoadjuvant chemotherapy was significantly greater in the pCR group than in the non-pCR group (p < 0.000066). The four FDG uptake indices were all strongly correlated with each other. A decrease in SUV(max-BSA-G) of 85.4% +/- 21.9% was found in pCR patients, versus 22.6% +/- 36.6% in non-pCR patients. DeltaSUV(max-BSA-G) <-60% predicted the pCR with an accuracy of 87% and DeltaSUVs were found to be only factors predictive of the pCR at multivariate analysis. An elevated baseline SUV was associated with high mitotic activity (p < 0.0016), tumour grading (p < 0.004), high nuclear pleomorphism score (p < 0.03) and negative hormonal receptor status (p < 0.005). CONCLUSION: In breast cancerpatients, after only one course of neoadjuvant chemotherapy the reduction in FDG uptake is an early and powerful predictor of pCR.
Authors: W Heller; D Mazhar; R Ward; H D Sinnett; C Lowdell; R Phillips; S Shousha; A Fayaz; C Palmieri; R C Coombes Journal: Oncol Rep Date: 2007-01 Impact factor: 3.906
Authors: I C Smith; A E Welch; A W Hutcheon; I D Miller; S Payne; F Chilcott; S Waikar; T Whitaker; A K Ah-See; O Eremin; S D Heys; F J Gilbert; P F Sharp Journal: J Clin Oncol Date: 2000-04 Impact factor: 44.544
Authors: Lale Kostakoglu; Fenghai Duan; Michael O Idowu; Paul R Jolles; Harry D Bear; Mark Muzi; Jean Cormack; John P Muzi; Daniel A Pryma; Jennifer M Specht; Linda Hovanessian-Larsen; John Miliziano; Sharon Mallett; Anthony F Shields; David A Mankoff Journal: J Nucl Med Date: 2015-09-10 Impact factor: 10.057
Authors: Marieke E Straver; Tjeerd S Aukema; Renato A Valdes Olmos; Emiel J T Rutgers; Kenneth G A Gilhuijs; Margaret E Schot; Wouter V Vogel; Marie-Jeanne T F D Vrancken Peeters Journal: Eur J Nucl Med Mol Imaging Date: 2010-02-04 Impact factor: 9.236
Authors: Michal E Schneider-Kolsky; Stewart Hart; Jane Fox; Peter Midolo; John Stuckey; Michael Hofman; Vinod Ganju Journal: Breast Cancer Res Date: 2010-06-21 Impact factor: 6.466